Arcutis Appoints Rob Scott, MD to Board of Directors
Arcutis Biotherapeutics appointed Rob Scott, MD, to its Board of Directors effective October 23, 2026. Scott is a former AbbVie Chief Medical Officer with over 40 years in drug development, tied to approvals including Skyrizi, Rinvoq, Venclexta, Repatha, and Lipitor, and served on the FDA Cardiac and Renal Drug Advisory Committee.
Key figures
- Effective date
- October 23, 2026
- Abbvie approvals
- over 14 major regulatory approvals
- Years experience
- over 40 years
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.